Greystone Associates, Aug 2011
challenging areas of therapeutic medicine. Patients diagnosed with conditions such as schizophrenia, Alzheimer's disease, Parkinson's disease, and manic depressive disorder are often not physically
Greystone Associates, Dec 2010
illnesses and conditions are treated.
Highlights
- Analyzes and evaluates inhaled drugs currently in development and assesses the market potential for existing and probable future products
- Examines
Greystone Associates, May 2009, Pages: 100
Factors
- Forecasts & Projections to 2011
Methodology:
Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers
Life Science Intelligence, Inc., Jan 2012, Pages: 101
founded, etc.)
- Competitive Landscape
- Technological Advantage
- Stage of Development
- Target Markets
- Financial Summary and Sales Forecasts
- Financing & Partnering Needs
- IP Position & Status
Jain PharmaBiotech, May 2012, Pages: 633
it will constitute a major and important component of the CNS market. Forecasts are made until 2021. By that time neuroprotection will be an established part of the neurological practice and measures will be available
Seed Planning, July 2007, Pages: 403
nationwide Japanese patient population statistics for all categories of diseases.
This book is designed to benefit people who are involved in searching patient population aiming to assess relevant markets
Espicom Business Intelligence Ltd, June 2009, Pages: 110
our forecasting period (2008-2018). However the harsh economic environment may force companies to place promising drugs on hold as they focus on lead projects rather than multiple programmes. To date
Espicom Business Intelligence Ltd, June 2009, Pages: 106
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Sales forecasts of products using the delivery
Espicom Business Intelligence Ltd, June 2009, Pages: 118
the delivery technology sector
- Products in development/approved utilising the delivery technology
- Sales forecasts of products utilising the delivery technology
- Competitor ratio analysis
Companies
WinterGreen Research, Inc., Jan 2006, Pages: 158
Medical Tunable Laser Market Opportunities, Strategies, and Forecasts, 2006 To 2012 Medical Tunable Laser are available in 2006 for commercial deployment. Tunable laser medical systems are used
Espicom Business Intelligence Ltd, June 2009, Pages: 126
. In addition, we forecast that controlled-release products in development from 17 key companies could generate additional sales of over US$5.1 billion by 2018.
Impact on product lifecycles
Controlled-release
Espicom Business Intelligence Ltd, Aug 2008, Pages: 88
our forecast period to 2014, the market will show negative growth as the emergence of new products is offset by the impact of generics on leading brands.
Current market leaders will launch a number
Jain PharmaBiotech, May 2012, Pages: 1037
to technologies, applications and geographical regions. Forecasts are made up to 2021. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip
Arrowhead Publishers, Aug 2006, Pages: 218
needs.
The Global Diabetes Market assesses the markets for diabetes therapeutics, as well as the markets for diagnostic products and those that treat diabetic complications. This new report incorporates
Markets and Markets, Sep 2009, Pages: 256
are the market forecasts and estimates from the period 2009-14?
- What are the major drivers and opportunities in the market?
- What is the competitive outlook, what are the major tools and services, who are the major
Espicom Business Intelligence Ltd, Jan 2011, Pages: 124
sales forecasts to 2015 for key technology areas
- Critical analyses of specialist developers driving the market onwards
The increasing number of new biological products, and the emergence
Key Note Publications Ltd, June 2003
Charity Funding Market Assessment 2003 A government consultation document - Private Action, Public Benefit, published by the Strategy Unit in September 2002 - recommends a radical change to the way
